MetaADEDB 2.0 @ LMMD
nitazoxanide
(YQNQNVDNTFHQSW-UHFFFAOYSA-N)
Structure
SMILES
CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+](=O)[O-]
Type(s)
Approved; Investigational; Vet_approved
ATC code(s)
P01AX11
Molecular Formula:
C12H9N3O5S
Molecular Weight:
307.282
Log P:
2.8251
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
1
TPSA:
142.35
CAS Number(s):
55981-09-4
Synonym(s)
1.
nitazoxanide
2.
Alinia
3.
Colufase
4.
Cryptaz
5.
Daxon
6.
Heliton
7.
NTZ
8.
Taenitaz
External Link(s)
MeSHC041747
PubChem Compound41684
BindingDB50075050
ChEBI94807
CHEMBLCHEMBL1401
DrugBankDB00507
DrugCentral1943
KEGGdr:D02486
Therapeutic Target DatabaseD08EBN
ZINC3956788
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1ChromaturiaFAERS: 19SIDER
US FAERS
2NauseaFAERS: 18SIDER
US FAERS
3HeadacheFAERS: 10SIDER
US FAERS
4Abdominal PainFAERS: 6SIDER
US FAERS
5ArthralgiaFAERS: 5US FAERS
6FatigueFAERS: 5US FAERS
7UrticariaFAERS: 5US FAERS
8VomitingFAERS: 4SIDER
US FAERS
9DizzinessFAERS: 3SIDER
US FAERS
10Drug ineffectiveFAERS: 3US FAERS
11DysuriaFAERS: 3SIDER
US FAERS
12HypersensitivityFAERS: 3SIDER
US FAERS
13TachycardiaFAERS: 3SIDER
US FAERS
14Abdominal discomfortFAERS: 2US FAERS
15ErythemaFAERS: 2US FAERS
16Feeling abnormalFAERS: 2SIDER
US FAERS
17Lip swellingFAERS: 2US FAERS
18PainFAERS: 2SIDER
US FAERS
19PallorFAERS: 2US FAERS
20PruritusFAERS: 2SIDER
US FAERS
21TremorFAERS: 2SIDER
US FAERS
22Weight decreasedFAERS: 2US FAERS
23Accidental exposure to product by childFAERS: 1US FAERS
24Accidental overdoseFAERS: 1US FAERS
25AphoniaFAERS: 1US FAERS
26AstheniaFAERS: 1SIDER
US FAERS
27AtelectasisFAERS: 1US FAERS
28Burning sensationFAERS: 1US FAERS
29Cardiac ArrestFAERS: 1US FAERS
30Chest PainFAERS: 1US FAERS
31Chest discomfortFAERS: 1US FAERS
32ChillsFAERS: 1SIDER
US FAERS
33DehydrationFAERS: 1US FAERS
34Drug ineffective for unapproved indicationFAERS: 1US FAERS
35DysarthriaFAERS: 1US FAERS
36DysgeusiaFAERS: 1US FAERS
37DyspepsiaFAERS: 1SIDER
US FAERS
38FlushingFAERS: 1US FAERS
39HepatitisFAERS: 1US FAERS
40Infrequent bowel movementsFAERS: 1US FAERS
41Joint swellingFAERS: 1US FAERS
42MalaiseFAERS: 1SIDER
US FAERS
43Maternal exposure during pregnancyFAERS: 1US FAERS
44Ocular icterusFAERS: 1US FAERS
45Oral fungal infectionFAERS: 1US FAERS
46PalpitationsFAERS: 1US FAERS
47Peripheral swellingFAERS: 1US FAERS
48Pre-existing condition improvedFAERS: 1US FAERS
49Productive CoughFAERS: 1US FAERS
50Rash erythematousFAERS: 1US FAERS
51Respiratory distressFAERS: 1US FAERS
52RetchingFAERS: 1US FAERS
53RhinitisFAERS: 1SIDER
US FAERS
54SomnolenceFAERS: 1SIDER
US FAERS
55SyncopeFAERS: 1SIDER
US FAERS
56Therapeutic response unexpectedFAERS: 1US FAERS
57ThirstFAERS: 1SIDER
US FAERS
58Unresponsive to stimuliFAERS: 1US FAERS
59Vulvovaginal painFAERS: 1US FAERS
60Alanine Aminotransferase IncreasedSIDER
61AnorexiaSIDER
62Back PainSIDER
63Blood creatinine increasedSIDER
64ConstipationSIDER
65Cramps of lower extremitiesSIDER
66Creatinine increasedSIDER
67DermatitisSIDER
68DiscomfortSIDER
69EpistaxisSIDER
70FlatulenceSIDER
71Gastrointestinal PainSIDER
72InfectionSIDER
73InfluenzaSIDER
74LeukocytosisSIDER
75MetrorrhagiaSIDER
76Musculoskeletal discomfortSIDER
77MyalgiaSIDER
78Pelvic PainSIDER
79PharyngitisSIDER
80Renal painSIDER
81ShockSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.